Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

Background Since it was suggested that B cells play a role in the pathogenesis of chronic graft-versus-host disease, rituximab, an anti-CD20 monoclonal antibody targeting B cells, has been shown to be effective in steroid-refractory, chronic graft-versus-host disease. However, most of the data were...

Full description

Bibliographic Details
Main Authors: Seok Jin Kim, Jong Wook Lee, Chul Won Jung, Chang Ki Min, Bin Cho, Ho Jin Shin, Joo Seop Chung, Hawk Kim, Won Sik Lee, Young Don Joo, Deok-Hwan Yang, Hoon Kook, Hyoung Jin Kang, Hyo Seop Ahn, Sung-Soo Yoon, Sang Kyun Sohn, Yoo Hong Min, Woo-Sung Min, Hee-Sook Park, Jong Ho Won
Format: Article
Language:English
Published: Ferrata Storti Foundation 2010-11-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/5791

Internet

https://haematologica.org/article/view/5791

Similar Items